France
· Delayed Price · Currency is EUR OSE Immunotherapeutics Statistics
Total Valuation
OSE Immunotherapeutics has a market cap or net worth of EUR 172.72 million. The enterprise value is 199.85 million.
| Market Cap | 172.72M |
| Enterprise Value | 199.85M |
Important Dates
The next estimated earnings date is Friday, September 27, 2024.
| Earnings Date | Sep 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
OSE Immunotherapeutics has 21.75 million shares outstanding.
| Shares Outstanding | 21.75M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 25.58% |
| Owned by Institutions (%) | 1.14% |
| Float | 15.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 2.34 |
| PS Ratio | 69.75 |
| PB Ratio | 7.46 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.69 |
| EV / Sales | 89.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.10 |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of 199.35.
| Current Ratio | 1.62 |
| Quick Ratio | 1.40 |
| Debt / Equity | 199.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.32 |
| Interest Coverage | -10.47 |
Financial Efficiency
Return on equity (ROE) is -82.70% and return on invested capital (ROIC) is -19.65%.
| Return on Equity (ROE) | -82.70% |
| Return on Assets (ROA) | -16.53% |
| Return on Capital (ROIC) | -19.65% |
| Revenue Per Employee | 40,491 |
| Profits Per Employee | -418,236 |
| Employee Count | 55 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +185.61% in the last 52 weeks. The beta is 0.91, so OSE Immunotherapeutics's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | +185.61% |
| 50-Day Moving Average | 6.90 |
| 200-Day Moving Average | 5.51 |
| Relative Strength Index (RSI) | 64.26 |
| Average Volume (20 Days) | 121,448 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OSE Immunotherapeutics had revenue of EUR 2.23 million and -23.00 million in losses. Loss per share was -1.18.
| Revenue | 2.23M |
| Gross Profit | 2.23M |
| Operating Income | -22.99M |
| Pretax Income | -23.22M |
| Net Income | -23.00M |
| EBITDA | -22.66M |
| EBIT | -22.99M |
| Loss Per Share | -1.18 |
Balance Sheet
The company has 18.67 million in cash and 45.80 million in debt, giving a net cash position of -27.13 million or -1.25 per share.
| Cash & Cash Equivalents | 18.67M |
| Total Debt | 45.80M |
| Net Cash | -27.13M |
| Net Cash Per Share | -1.25 |
| Equity (Book Value) | 22.98M |
| Book Value Per Share | 1.06 |
| Working Capital | 11.68M |
Cash Flow
In the last 12 months, operating cash flow was -19.76 million and capital expenditures -16,000, giving a free cash flow of -19.78 million.
| Operating Cash Flow | -19.76M |
| Capital Expenditures | -16,000 |
| Free Cash Flow | -19.78M |
| FCF Per Share | -0.91 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,032.15% |
| Pretax Margin | -1,042.75% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -888.19% |
Dividends & Yields
OSE Immunotherapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -14.86% |
| FCF Yield | -11.45% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |